Jeffrey E Rubnitz

List of Publications by Year
in descending order

244 papers	18,569 citations	13078 68 h-index	14801 128 g-index
309 all docs	309 docs citations	309 times ranked	17674 citing authors

#	Article	IF	Citations
1	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	30.1	1,079
2	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology, The, 2009, 10, 147-156.	10.8	872
3	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 955-959.	15.4	574
4	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet, The, 2007, 370, 240-250.	12.1	562
5	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, The, 2010, 11, 543-552.	10.8	524
6	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 2007, 109, 926-935.	1.4	420
7	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 2004, 104, 2690-2696.	1.4	415
8	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	412
9	Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 2004, 104, 3679-3687.	1.4	407
10	Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, The, 1998, 351, 550-554.	12.1	404
11	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	393
12	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	12.1	391
13	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	15.4	295
14	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	15.4	288
15	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2007, 297, 1207.	7.0	268
16	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	36.2	250
17	Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 2002, 100, 52-58.	1.4	240
18	The genomic landscape of core-binding factor acute myeloid leukemias. Nature Genetics, 2016, 48, 1551-1556.	20.4	222

#	Article	IF	Citations
19	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2012, 22, 683-697.	16.8	217
20	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	15.4	214
21	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	1.4	205
22	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of Clinical Oncology, 2019, 37, 2246-2256.	15.4	204
23	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 2001, 97, 3727-3732.	1.4	195
24	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 3625-3632.	15.4	190
25	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	184
26	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology, The, 2015, 16, 465-474.	10.8	183
27	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	15.4	183
28	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	1.4	181
29	Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia. Journal of Clinical Oncology, 2003, 21, 3084-3091.	15.4	180
30	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 2302-2309.	15.4	178
31	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 2012, 120, 468-472.	1.4	178
32	Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 2002, 100, 2399-2402.	1.4	174
33	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12944-12949.	7.6	172
34	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	7.0	160
35	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 2011, 118, 223-230.	1.4	160
36	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood, 2009, 113, 5083-5089.	1.4	159

#	Article	IF	Citations
37	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	14.2	158
38	Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia. JAMA - Journal of the American Medical Association, 2000, 284, 2222.	7.0	157
39	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	15.4	156
40	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)â€“rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood, 2010, 116, 2644-2650.	1.4	147
41	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. Journal of Clinical Oncology, 2011, 29, 3293-3300.	15.4	143
42	Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2002, 288, 2001.	7.0	138
43	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	15.4	129
44	Death during induction therapy and first remission of acute leukemia in childhood. Cancer, 2004, 101, 1677-1684.	4.1	127
45	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	15.4	123
46	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology, 2003, 123, 243-252.	2.7	122
47	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	15.4	106
48	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncology, The, 2020, 21, 551-560.	10.8	103
49	Childhood Acute Lymphoblastic Leukemia With the MLL-ENL Fusion and t(11;19)(q23;p13.3) Translocation. Journal of Clinical Oncology, 1999, 17, 191-191.	15.4	102
50	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 4094-4101.	15.4	98
51	Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study. Blood, 1997, 89, 1143-1146.	1.4	91
52	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood, 2006, 108, 3997-4002.	1.4	91
53	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	89
54	Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. JAMA Oncology, 2020, 6, 552.	7.3	89

#	Article	IF	Citations
55	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer, 2007, 109, 157-163.	4.1	88
56	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer, 2008, 113, 376-382.	4.1	88
57	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITDâ€“Positive Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 5758-5768.	7.2	88
58	Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2006, 108, 3302-3304.	1.4	87
59	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer, 2008, 113, 522-529.	4.1	85
60	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood, 2009, 114, 3764-3768.	1.4	83
61	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.8	83
62	How I treat pediatric acute myeloid leukemia. Blood, 2012, 119, 5980-5988.	1.4	81
63	RelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host. MBio, 2017, 8, .	4.4	80
64	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer, 2005, 103, 368-376.	4.1	79
65	Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 2186-2191.	15.4	79
66	Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 935-945.	2.4	77
67	Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. Journal of Clinical Oncology, 2015, 33, 4247-4258.	15.4	77
68	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		77
69	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	7.2	74
70	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7936-7941.	15.4	70
71	Childhood acute myeloid leukaemia. British Journal of Haematology, 2012, 159, 259-276.	2.7	69
72	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia, 2020, 34, 735-745.	7.5	68

#	Article	IF	Citations
73	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood, 2012, 119, e67-e75.	1.4	66
74	Current Management of Childhood Acute Myeloid Leukemia. Paediatric Drugs, 2017, 19, 1-10.	3.2	66
75	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 4217-4224.	15.4	65
76	Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight, 2018, 3, .	5.0	62
77	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Current Opinion in Hematology, 2002, 9, 345-352.	2.6	61
78	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicinâ€“Containing Chemotherapy. Clinical Cancer Research, 2013, 19, 1620-1627.	7.2	61
79	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer, 2014, 120, 1514-1519.	4.1	61
80	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	1.4	59
81	Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer, 2012, 118, 5989-5996.	4.1	59
82	Molecular Genetics of Childhood Leukemias. Journal of Pediatric Hematology/Oncology, 1998, 20, 1-11.	0.6	58
83	Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10338-10343.	7.6	57
84	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics, 2012, 11, 921-929.	3.7	57
85	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. Journal of Clinical Oncology, 2015, 33, 610-615.	15.4	57
86	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer, 2014, 120, 1985-1992.	4.1	54
87	Impact of age on outcome of pediatric acute myeloid leukemia. Cancer, 2006, 106, 2495-2502.	4.1	52
88	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatric Blood and Cancer, 2006, 47, 931-935.	1.6	51
89	Genetic Variants in Cytosolic 5â€²-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 9-23.	2.4	51
90	How I treat pediatric acute myeloid leukemia. Blood, 2021, 138, 1009-1018.	1.4	51

#	Article	IF	Citations
91	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2011, 103, 893-905.	6.4	50
92	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, The, 2018, 18, 854-863.	8.9	50
93	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. Pediatric Blood and Cancer, 2007, 48, 10-15.	1.6	46
94	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood, 2002, 100, 43-47.	1.4	45
95	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	2.4	44
96	Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6â€“RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genetics and Cytogenetics, 2006, 169, 50-57.	0.9	44
97	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	2.4	44
98	Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, 3, 194-207.	5.8	44
99	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treatment Reviews, 2003, 29, 31-44.	8.0	43
100	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood, 2013, 121, 4366-4376.	1.4	43
101	Minimal Residual Disease Quantitation in Acute Myeloid Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S281-S285.	1.8	42
102	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer, 2013, 119, 4036-4043.	4.1	42
103	Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood and Cancer, 2015, 62, 1468-1472.	1.6	42
104	Ontogeny and Sorafenib Metabolism. Clinical Cancer Research, 2012, 18, 5788-5795.	7.2	40
105	Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. European Journal of Oncology Nursing, 2009, 13, 156-163.	2.2	39
106	Decreased relapsed rate and treatmentâ€related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer, 2017, 123, 3791-3798.	4.1	39
107	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. Journal of Clinical Investigation, 2017, 128, 369-380.	8.2	39
108	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. Neoplasia, 1999, 1, 253-261.	5.3	37

#	Article	IF	Citations
109	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 2072-2081.	15.4	37
110	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	13.2	37
111	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	2.4	36
112	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatric Blood and Cancer, 2005, 44, 63-69.	1.6	35
113	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica, 2014, 99, 299-307.	3.5	35
114	Cutaneous Infection Caused by Macrophomina phaseolina in a Child with Acute Myeloid Leukemia. Journal of Clinical Microbiology, 2009, 47, 1969-1972.	4.4	32
115	Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer, 2012, 118, 6253-6259.	4.1	32
116	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 2015, 168, 94-101.	2.7	32
117	RRM1 and RRM2 Pharmacogenetics: Association with Phenotypes in HapMap Cell Lines and Acute Myeloid Leukemia Patients. Pharmacogenomics, 2013, 14, 1449-1466.	1.4	29
118	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer, 2016, 63, 1546-1551.	1.6	29
119	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	13.2	29
120	Identification of Predictive Markers of Cytarabine Response in AML by Integrative Analysis of Gene-Expression Profiles with Multiple Phenotypes. Pharmacogenomics, 2011, 12, 327-339.	1.4	28
121	Childhood Acute Myeloid Leukemia. Current Treatment Options in Oncology, 2008, 9, 95-105.	3.1	27
122	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 2013, 119, 2061-2066.	4.1	27
123	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. Oncotarget, 2018, 9, 26711-26723.	2.1	27
124	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer, 2010, 116, 98-105.	4.1	25
125	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2019, 134, 285-285.	1.4	24
126	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2013, 60, 1161-1164.	1.6	23

#	Article	IF	Citations
127	Voriconazole Prophylaxis in Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e451-e455.	2.0	23
128	Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124, 1025-1035.	4.1	23
129	Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2002, 24, 561-565.	0.6	22
130	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	5.8	22
131	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. Leukemia Research, 2011, 35, 1321-1329.	1.1	21
132	Childhood Acute Lymphoblastic Leukemia. Oncologist, 1997, 2, 374-380.	4.1	21
133	Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nature Communications, 2022, 13, .	13.2	21
134	Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Current Opinion in Hematology, 1997, 4, 233-241.	2.6	20
135	Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. Leukemia Research, 2004, 28, 349-352.	1.1	20
136	Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2005, 44, 138-141.	1.6	20
137	Molecular diagnostics in the treatment of leukemia. Current Opinion in Hematology, 1999, 6, 229.	2.6	18
138	Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. Journal of Clinical Oncology, 2023, 41, 2963-2974.	15.4	18
139	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.6	17
140	PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics, 2009, 25, 2013-2019.	4.2	16
141	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 2012, 156, 275-279.	2.7	16
142	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research, 2019, 25, 7320-7330.	7.2	16
143	Concurrent translocations ofMLL andCBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	3.3	15
144	Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. Journal of Clinical Oncology, 2011, 29, e230-e233.	15.4	15

#	Article	IF	Citations
145	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	4.1	14
146	Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	14
147	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	14
148	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. Leukemia, 2022, 36, 1951-1960.	7.5	14
149	Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood, 2024, 143, 619-630.	1.4	14
150	Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. European Journal of Paediatric Neurology, 2010, 14, 78-79.	1.5	13
151	Randomized trial of 2 dosages of prophylactic granulocyteâ€“colonyâ€stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. Cancer, 2011, 117, 1313-1320.	4.1	13
152	Definition of cure in childhood acute myeloid leukemia. Cancer, 2014, 120, 2490-2496.	4.1	13
153	Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML. Oncotarget, 2018, 9, 34859-34875.	2.1	13
154	Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?. Expert Review of Hematology, 2014, 7, 427-429.	2.1	12
155	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	12
156	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3â€ITD AML. Clinical and Translational Science, 2019, 12, 641-647.	3.1	12
157	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. Leukemia, 2021, 35, 2258-2273.	7.5	12
158	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Advances, 2022, 6, 521-527.	5.4	11
159	Correction of deletions in mammalian cells by gene conversion. Somatic Cell and Molecular Genetics, 1987, 13, 183-190.	0.7	10
160	Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatric Blood and Cancer, 2008, 50, 866-868.	1.6	10
161	Spinal epidural lipomatosis in children with hematologic malignancies. Annals of Hematology, 2011, 90, 1067-1074.	1.8	10
162	Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study. PLoS ONE, 2015, 10, e0135904.	2.5	9

#	Article	IF	Citations
163	Comprehensive Ara-C SNP Score Predicts Leukemic Cell Intracellular Ara-CTP Levels in Pediatric Acute Myeloid Leukemia Patients. Pharmacogenomics, 2018, 19, 1101-1110.	1.4	9
164	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal, 2019, 19, 305-314.	2.2	9
165	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of Clinical Oncology, 2022, 40, 772-783.	15.4	9
166	Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. Blood, 2014, 124, 972-972.	1.4	8
167	Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia. Nature Communications, 2023, 14, .	13.2	8
168	Isolated Nasal Septum Necrosis Caused by Aspergillus flavus in an Immunocompromised Child. Pediatric Infectious Disease Journal, 2011, 30, 627-629.	2.0	7
169	Clinical significance ofin vivocytarabine-induced gene expression signature in AML. Leukemia and Lymphoma, 2016, 57, 909-920.	1.4	7
170	Global Proteomic Profiling of Pediatric AML: A Pilot Study. Cancers, 2021, 13, 3161.	3.8	7
171	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital â€“ Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 757-757.	1.4	7
172	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 2021, 4, e2128385.	6.0	7
173	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical Cancer Research, 2022, 28, 2536-2546.	7.2	7
174	Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML. Blood Advances, 2023, 7, 1769-1783.	5.4	7
175	A new genomic framework to categorize pediatric acute myeloid leukemia. Nature Genetics, 2024, 56, 281-293.	20.4	7
176	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. Cancers, 2020, 12, 3024.	3.8	6
177	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	6
178	Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. Blood, 2018, 132, 1536-1536.	1.4	6
179	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	6
180	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leukemia and Lymphoma, 2017, 58, 247-250.	1.4	5

#	Article	IF	Citations
181	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	5
182	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2018, 132, 3966-3966.	1.4	5
183	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Advances, 2022, 6, 2824-2834.	5.4	5
184	Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML. Bone Marrow Transplantation, 2023, 58, 328-331.	2.4	5
185	SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. Blood Advances, 2023, 7, 2538-2550.	5.4	5
186	Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia, 2023, 37, 1782-1791.	7.5	5
187	Constitutive behavior of methionyl-tRNA synthetase compared to repressible behavior of methionine adenosyltransferase in mammalian cells. Biochimica Et Biophysica Acta - General Subjects, 1981, 677, 269-273.	2.5	4
188	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. Pediatric Blood and Cancer, 2008, 50, 542-548.	1.6	4
189	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Pediatric Blood and Cancer, 2017, 64, e26632.	1.6	3
190	Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study. Blood, 2018, 132, 655-655.	1.4	3
191	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	1.4	3
192	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood, 2020, 136, 23-24.	1.4	3
193	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. Blood, 2010, 116, 1073-1073.	1.4	3
194	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. Blood, 2015, 126, 4872-4872.	1.4	3
195	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. Blood, 2009, 114, 114-114.	1.4	3
196	Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16. Blood Advances, 2022, 6, 6131-6134.	5.4	3
197	Acute Myeloid Leukemia in Children. , 2018, , 981-993.		2
198	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. Clinical Chemistry, 2020, 66, 518-522.	3.5	2

#	Article	IF	Citations
199	An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Childrenâ€™s Oncology Group Protocols AAML0531 and 03P1 and St Jude Childrenâ€™s Research Hospital Protocol AML02. Blood, 2014, 124, 277-277.	1.4	2
200	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. Blood, 2015, 126, 1345-1345.	1.4	2
201	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 4474-4474.	1.4	2
202	Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. Blood, 2018, 132, 2758-2758.	1.4	2
203	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood, 2019, 134, 379-379.	1.4	2
204	Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. Blood, 2023, 141, 800-805.	1.4	2
205	Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia. Blood Advances, 2023, 7, 3651-3657.	5.4	2
206	MRD in AML: it's time to face the FACS. Blood, 2003, 101, 3341-3341.	1.4	1
207	POST: A framework for set-based association analysis in high-dimensional data. Methods, 2018, 145, 76-81.	3.9	1
208	Activity of venetoclax against relapsed acute undifferentiated leukemia. Cancer, 2021, 127, 2608-2611.	4.1	1
209	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. Blood, 2019, 134, 918-918.	1.4	1
210	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27.	1.4	1
211	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. Blood, 1999, 93, 315-320.	1.4	1
212	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	1.4	1
213	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. Blood, 2018, 132, 290-290.	1.4	1
214	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. Blood, 2019, 134, 1429-1429.	1.4	1
215	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	1.4	1
216	Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer, 0, , .	4.1	1

#	Article	IF	Citations
217	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
218	POST: A framework for set-based association analysis in high-dimensional data. , 2017, , .		0
219	Minimal Residual Diseaseâ€“Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	1.4	0
220	5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.. Blood, 2009, 114, 593-593.	1.4	0
221	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	1.4	0
222	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. Blood, 2010, 116, 849-849.	1.4	0
223	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Mul^nster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0
224	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	1.4	0
225	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
226	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	1.4	0
227	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2434-2434.	1.4	0
228	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	1.4	0
229	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. Blood, 2016, 128, 2838-2838.	1.4	0
230	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.3	0
231	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 178-178.	1.4	0
232	Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	3.3	0
233	Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML. Blood, 2021, 138, 3429-3429.	1.4	0
234	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. Blood, 2021, 138, 4415-4415.	1.4	0

#	Article	IF	Citations
235	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. Blood, 2021, 138, 2295-2295.	1.4	0
236	Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. Blood, 2021, 138, LBA-4-LBA-4.	1.4	0
237	78. Non-Invasive Prediction of Invasive Fungal Infection by Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing (mcfDNA NGS) in Pediatric Patients with Relapsed or Refractory Leukemia. Open Forum Infectious Diseases, 2021, 8, S51-S51.	0.9	0
238	Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis. British Journal of Haematology, 2023, 200, 338-343.	2.7	0
239	Neurocognitive and psychosocial outcomes in survivors of childhood leukemia with Down syndrome. Cancer Medicine, 2024, 13, .	2.9	0
240	Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion. Leukemia, 2024, 38, 981-990.	7.5	0
241	Household income and healthâ€related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Medicine, 2024, 13, .	2.9	0
242	Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. Blood Advances, 2024, 8, 3200-3213.	5.4	0
243	Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 0, , .	7.2	0
244	Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. Blood, 0, , .	1.4	0